Pre-clinical development of PPCM Vaginal Microbicide

Medicine & Life Sciences

1. Contraceptive Agents 100%
2. Anti-Infective Agents 79%
3. Sexually Transmitted Diseases 51%
4. HIV 41%
5. Contraception 26%
6. National Institute of Child Health and Human Development (U.S.) 25%
7. Foams and Jellies Vaginal Creams 25%
8. Epidemics 22%
9. Gels 21%
10. Reverse Transcriptase Inhibitors 20%
11. Gonorrhea 20%
12. Safety 20%
13. Nonoxynol 13%
14. National Institute of Allergy and Infectious Diseases (U.S.) 13%
15. Cell Culture Techniques 13%
16. Clinical Trial Protocols 13%
17. Contraceptive Effectiveness 13%
18. polyanions 12%
19. Female Contraceptive Devices 12%
20. Laboratory Infection 12%
21. Rabbits 12%
22. Herpes Genitalis 11%
23. Tenofovir 10%
24. Population Growth 10%
25. Clinical Trials, Phase I 10%
26. Human Herpesvirus 2 10%
27. Organized Financing 10%
28. Semen 9%
29. Surface-Active Agents 8%
30. Infections 8%
31. Spermatozoa 7%
32. Polymers 7%
33. In Vitro Techniques 7%
34. Prescriptions 7%
35. Epithelial Cells 6%
36. Public Health 6%
37. Viruses 5%
38. Clinical Trials 5%
39. T-Lymphocytes 5%